Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The buyout, announced last summer, drew the attention of federal regulators at the Federal Trade Commission, concerned that competition for ambulatory surgery services would be stifled by the merger. To appease the agency, Ascension has agreed to divest from some centers previously owned by Amsurg.
When Mayo Clinic and Microsoft announced last week that they’re partnering to develop a frontier AI model for healthcare, observers could see where Mayo’s expertise in advanced digital medicine would interest Microsoft. The Big Tech behemoth has not been coy about its healthcare ambitions.
Senate Bill 196 was signed into law by Gov. Ned Lamont a year after the state saw Prospect Medical Holdings, an investor-backed health system, fall into bankruptcy as investors extracted hundreds of millions of dollars in fees from its hospitals.
The lawsuit against Find a Black Doctor was filed by Travis Morrell, MD—a dermatologist based in Colorado—who alleges he was harmed by being excluded from the directory on the basis of race. His case has the backing of the conservative-aligned advocacy group Do No Harm.
Details are slim, but Ōura Health confirmed it submitted a draft registration with the Securities and Exchange Commission. The company received $900 million in new funding from investors in October.
The same day that Tennessee Gov. Bill Lee signed a bill that would force pharmacy benefit managers to divest from retail pharmacies, CVS Health filed a lawsuit to block its implementation.
Quorum Health said the move will allow it to save money through tax exemptions and provide its 11 hospitals with access to the 340B Drug Pricing Program. The health system is majority-owned by Goldentree Asset Management.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.